At the time of writing, Vertex Pharmaceuticals, Inc. [VRTX] stock is trading at $481.71, up 1.17%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VRTX shares have gain 5.80% over the last week, with a monthly amount glided 0.64%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Barclays downgraded its rating to Equal Weight on August 05, 2024, and elevated its price target to $509. On June 27, 2024, Redburn Atlantic initiated with a Buy rating and assigned a price target of $545 on the stock. Evercore ISI upgraded its rating to a Outperform but stick to its price target of $438 on April 11, 2024. Wolfe Research initiated its recommendation with a Outperform and recommended $515 as its price target on February 15, 2024. Evercore ISI downgraded its rating to In-line for this stock on February 06, 2024, and upped its price target to $438. In a note dated February 02, 2024, Bernstein downgraded an Mkt Perform rating on this stock.
For the past year, the stock price of Vertex Pharmaceuticals, Inc. fluctuated between $341.90 and $510.64. Currently, Wall Street analysts expect the stock to reach $381.77 within the next 12 months. Vertex Pharmaceuticals, Inc. [NASDAQ: VRTX] shares were valued at $481.71 at the most recent close of the market. An investor can expect a potential drop of -20.75% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
According to Vertex Pharmaceuticals, Inc. [NASDAQ:VRTX], the company’s sales were 10.32B for trailing twelve months, which represents an 6.02% jump. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.04%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is -0.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.03 and Total Capital is -0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 477.42 points at the first support level, and at 473.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 484.44, and for the 2nd resistance point, it is at 487.18.
Ratios To Look Out For
It is important to note that Vertex Pharmaceuticals, Inc. [NASDAQ:VRTX] has a current ratio of 2.52. As well, the Quick Ratio is 2.26, while the Cash Ratio is 1.29. Considering the valuation of this stock, the price to sales ratio is 12.04, the price to book ratio is 8.41.
Transactions by insiders
Recent insider trading involved Biller Jonathan, EVP and Chief Legal Officer, that happened on Oct 02 ’24 when 999.0 shares were sold. Officer, Biller Jonathan completed a deal on Oct 02 ’24 to buy 999.0 shares. Meanwhile, Executive Chairman LEIDEN JEFFREY M sold 3784.0 shares on Aug 30 ’24.
